Investments
196Portfolio Exits
28Funds
19About Sanderling Ventures
Founded in 1979, Sanderling is among the oldest investment firms dedicated to building new biomedical companies. Sanderling demonstrates that significant companies are best built in close working partnerships with entrepreneurs.

Want to inform investors similar to Sanderling Ventures about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Sanderling Ventures News
Jun 19, 2021
ViaCyte , a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Capital Partners, Invus Group, Asymmetry Ventures, and Artis Ventures. The company intends to use the funds to advance its portfolio of stem cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes. Led by Michael Yang, President and Chief Executive Officer, and Brittany Bradrick, Chief Financial Officer and Chief Operating Officer, ViaCyte is a regenerative medicine company developing novel cell replacement therapies based on two major technological advances: cell replacement therapies derived from pluripotent stem cells and medical device systems for cell encapsulation and implantation. The company’s first product candidates are being developed as potential long-term treatments for patients with type 1 diabetes to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with such companies as CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California.
Sanderling Ventures Investments
196 Investments
Sanderling Ventures has made 196 investments. Their latest investment was in TheraVida as part of their Debt - II on February 2, 2023.

Sanderling Ventures Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
2/21/2023 | Debt - II | TheraVida | $0.2M | No | 1 | |
3/22/2022 | Series A - III | Trefoil Therapeutics | $11.97M | Yes | 1 | |
6/23/2021 | Series B - II | Glycomine | $35M | No | 12 | |
6/9/2021 | Series D - IV | |||||
3/12/2021 | Series D |
Date | 2/21/2023 | 3/22/2022 | 6/23/2021 | 6/9/2021 | 3/12/2021 |
---|---|---|---|---|---|
Round | Debt - II | Series A - III | Series B - II | Series D - IV | Series D |
Company | TheraVida | Trefoil Therapeutics | Glycomine | ||
Amount | $0.2M | $11.97M | $35M | ||
New? | No | Yes | No | ||
Co-Investors | |||||
Sources | 1 | 1 | 12 |
Sanderling Ventures Portfolio Exits
28 Portfolio Exits
Sanderling Ventures has 28 portfolio exits. Their latest portfolio exit was CalciMedica on November 21, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
11/21/2022 | Acquired | 1 | |||
7/11/2022 | Acquired | 9 | |||
8/24/2020 | Acquired | 4 | |||
Date | 11/21/2022 | 7/11/2022 | 8/24/2020 | ||
---|---|---|---|---|---|
Exit | Acquired | Acquired | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 1 | 9 | 4 |
Sanderling Ventures Acquisitions
1 Acquisition
Sanderling Ventures acquired 1 company. Their latest acquisition was Pacira Biosciences on March 05, 2007.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
3/5/2007 | Debt | $111.25M | Acq - Fin |
Date | 3/5/2007 |
---|---|
Investment Stage | Debt |
Companies | |
Valuation | |
Total Funding | $111.25M |
Note | Acq - Fin |
Sources |
Sanderling Ventures Fund History
19 Fund Histories
Sanderling Ventures has 19 funds, including Sanderling I.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/30/2008 | Sanderling I | Early-Stage Venture Capital | Closed | $7M | 1 |
5/1/2005 | Sanderling Limited VI | Co-Investment Fund | Closed | $8M | 1 |
5/1/2005 | Sanderling Beteiligungs | Co-Investment Fund | Closed | $7M | 1 |
5/1/2005 | Sanderling VI LP | ||||
5/1/2004 | Sanderling VI Co-Investment LP |
Closing Date | 4/30/2008 | 5/1/2005 | 5/1/2005 | 5/1/2005 | 5/1/2004 |
---|---|---|---|---|---|
Fund | Sanderling I | Sanderling Limited VI | Sanderling Beteiligungs | Sanderling VI LP | Sanderling VI Co-Investment LP |
Fund Type | Early-Stage Venture Capital | Co-Investment Fund | Co-Investment Fund | ||
Status | Closed | Closed | Closed | ||
Amount | $7M | $8M | $7M | ||
Sources | 1 | 1 | 1 |
Sanderling Ventures Team
14 Team Members
Sanderling Ventures has 14 team members, including current Managing Director, Robert McNeil.
Name | Work History | Title | Status |
---|---|---|---|
Robert McNeil | Managing Director | Current | |
Name | Robert McNeil | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Managing Director | ||||
Status | Current |